6PHB

Pfs25 in complex with the human transmission blocking antibody 2530


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2 Å
  • R-Value Free: 0.209 
  • R-Value Work: 0.177 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history

Literature

Potent antibody lineage against malaria transmission elicited by human vaccination with Pfs25.

McLeod, B.Miura, K.Scally, S.W.Bosch, A.Nguyen, N.Shin, H.Kim, D.Volkmuth, W.Ramisch, S.Chichester, J.A.Streatfield, S.Woods, C.Schief, W.R.Emerling, D.King, C.R.Julien, J.P.

(2019) Nat Commun 10: 4328-4328

  • DOI: 10.1038/s41467-019-11980-6
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • Transmission-blocking vaccines have the potential to be key contributors to malaria elimination. Such vaccines elicit antibodies that inhibit parasites during their development in Anopheles mosquitoes, thus breaking the cycle of transmission. To date ...

    Transmission-blocking vaccines have the potential to be key contributors to malaria elimination. Such vaccines elicit antibodies that inhibit parasites during their development in Anopheles mosquitoes, thus breaking the cycle of transmission. To date, characterization of humoral responses to Plasmodium falciparum transmission-blocking vaccine candidate Pfs25 has largely been conducted in pre-clinical models. Here, we present molecular analyses of human antibody responses generated in a clinical trial evaluating Pfs25 vaccination. From a collection of monoclonal antibodies with transmission-blocking activity, we identify the most potent transmission-blocking antibody yet described against Pfs25; 2544. The interactions of 2544 and three other antibodies with Pfs25 are analyzed by crystallography to understand structural requirements for elicitation of human transmission-blocking responses. Our analyses provide insights into Pfs25 immunogenicity and epitope potency, and detail an affinity maturation pathway for a potent transmission-blocking antibody in humans. Our findings can be employed to guide the design of improved malaria transmission-blocking vaccines.


    Organizational Affiliation

    PATH's Malaria Vaccine Initiative, 455 Massachusetts Avenue NW Suite 1000, Washington, DC, 20001, USA.,Department of Biochemistry, University of Toronto, 1 King's College Circle, Toronto, ON, M5S 1A8, Canada. jean-philippe.julien@sickkids.ca.,Atreca, 500 Saginaw Drive, Redwood City, CA, 94063-4750, USA.,Department of Biochemistry, University of Toronto, 1 King's College Circle, Toronto, ON, M5S 1A8, Canada.,Department of Immunology, University of Toronto, 1 King's College Circle, Toronto, ON, M5S 1A8, Canada. jean-philippe.julien@sickkids.ca.,Program in Molecular Medicine, The Hospital for Sick Children Research Institute, 686 Bay Street, Toronto, ON, M5G 0A4, Canada. jean-philippe.julien@sickkids.ca.,Gene Therapy Program & Orphan Disease Center, Perelman School of Medicine, The University of Pennsylvania, Philadelphia, PA, 19104, USA.,Fraunhofer USA Center for Molecular Biotechnology CMB, 9 Innovation Way, Newark, DE, 19711, USA.,Program in Molecular Medicine, The Hospital for Sick Children Research Institute, 686 Bay Street, Toronto, ON, M5G 0A4, Canada.,Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA, 92037, USA.,Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 12735 Twinbrook Parkway, Rockville, MD, 20852, USA.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
25 kDa ookinete surface antigen
I, E
184Plasmodium falciparum (isolate NF54)Mutation(s): 0 
Find proteins for P13829 (Plasmodium falciparum (isolate NF54))
Go to UniProtKB:  P13829
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetails
2530 Antibody Fab, Light Chain
C, A
215N/AMutation(s): 0 
Protein Feature View is not available: No corresponding UniProt sequence found.
Entity ID: 3
MoleculeChainsSequence LengthOrganismDetails
2530 Antibody Fab, Heavy Chain
D, B
220N/AMutation(s): 0 
Protein Feature View is not available: No corresponding UniProt sequence found.
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
EDO
Query on EDO

Download SDF File 
Download CCD File 
A, B, C, D, I
1,2-ETHANEDIOL
ETHYLENE GLYCOL
C2 H6 O2
LYCAIKOWRPUZTN-UHFFFAOYSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2 Å
  • R-Value Free: 0.209 
  • R-Value Work: 0.177 
  • Space Group: P 31
Unit Cell:
Length (Å)Angle (°)
a = 114.599α = 90.00
b = 114.599β = 90.00
c = 98.181γ = 120.00
Software Package:
Software NamePurpose
PHENIXrefinement
XDSdata scaling
PHASERphasing
PHENIXrefinement
XDSdata reduction

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Bill & Melinda Gates FoundationCanadaOPP1108403

Revision History 

  • Version 1.0: 2019-10-02
    Type: Initial release
  • Version 1.1: 2019-10-09
    Type: Data collection, Database references